Spinal Muscular Atrophy drug: regulatory approval should guide Kerala’s procurement policy, say experts

Experts argue that Kerala should prioritize procuring a regulatory-approved generic formulation of the Spinal Muscular Atrophy drug over the original molecule, which is significantly more expensive. B. Ekbal highlights the cost disparity, stating the generic version is available at a fraction of the price.